247 related articles for article (PubMed ID: 33783927)
1.
Ye W; Lin Y; Bezabeh T; Ma C; Liang J; Zhao J; Ouyang T; Tang W; Wu R
NMR Biomed; 2021 Jun; 34(6):e4505. PubMed ID: 33783927
[TBL] [Abstract][Full Text] [Related]
2. Nuclear magnetic resonance-based metabolomics and metabolic pathway networks from patient-matched esophageal carcinoma, adjacent noncancerous tissues and urine.
Liang JH; Lin Y; Ouyang T; Tang W; Huang Y; Ye W; Zhao JY; Wang ZN; Ma CC
World J Gastroenterol; 2019 Jul; 25(25):3218-3230. PubMed ID: 31333313
[TBL] [Abstract][Full Text] [Related]
3.
Lin Y; Ma C; Bezabeh T; Wang Z; Liang J; Huang Y; Zhao J; Liu X; Ye W; Tang W; Ouyang T; Wu R
Int J Cancer; 2019 Sep; 145(6):1679-1689. PubMed ID: 30720869
[TBL] [Abstract][Full Text] [Related]
4. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
[TBL] [Abstract][Full Text] [Related]
5. Revealing the metabonomic variation of EC using ¹H-NMR spectroscopy and its association with the clinicopathological characteristics.
Hasim A; Ma H; Mamtimin B; Abudula A; Niyaz M; Zhang LW; Anwer J; Sheyhidin I
Mol Biol Rep; 2012 Sep; 39(9):8955-64. PubMed ID: 22736106
[TBL] [Abstract][Full Text] [Related]
6. NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer.
Zheng H; Dong B; Ning J; Shao X; Zhao L; Jiang Q; Ji H; Cai A; Xue W; Gao H
Clin Chim Acta; 2020 Feb; 501():241-251. PubMed ID: 31758937
[TBL] [Abstract][Full Text] [Related]
7. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers.
Xu J; Chen Y; Zhang R; Song Y; Cao J; Bi N; Wang J; He J; Bai J; Dong L; Wang L; Zhan Q; Abliz Z
Mol Cell Proteomics; 2013 May; 12(5):1306-18. PubMed ID: 23397110
[TBL] [Abstract][Full Text] [Related]
8. 1H-NMR based metabonomic profiling of human esophageal cancer tissue.
Wang L; Chen J; Chen L; Deng P; Bu Q; Xiang P; Li M; Lu W; Xu Y; Lin H; Wu T; Wang H; Hu J; Shao X; Cen X; Zhao YL
Mol Cancer; 2013 Apr; 12():25. PubMed ID: 23556477
[TBL] [Abstract][Full Text] [Related]
9.
Ouyang T; Ma C; Zhao Y; Ye W; Zhao J; Cai R; Zhang H; Zheng P; Lin Y
Front Oncol; 2023; 13():1082841. PubMed ID: 36756157
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Perturbation and Potential Markers in Patients with Esophageal Cancer.
Zhu X; Wang K; Liu G; Wang Y; Xu J; Liu L; Li M; Shi J; Aa J; Yu L
Gastroenterol Res Pract; 2017; 2017():5469597. PubMed ID: 28512469
[TBL] [Abstract][Full Text] [Related]
11. Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with the progression of gastroesophageal cancer.
Che J; Zhao Y; Gu B; Li S; Li Y; Pan K; Sun T; Han X; Lv J; Zhang S; Fan B; Li C; Wang C; Wang J; Zhang T
BMC Cancer; 2023 Dec; 23(1):1238. PubMed ID: 38102546
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry.
Wang D; Tan G; Wang H; Chen P; Hao J; Wang Y
J Pharm Biomed Anal; 2019 Mar; 166():357-363. PubMed ID: 30690249
[TBL] [Abstract][Full Text] [Related]
13. Serum metabolomic signatures of lymph node metastasis of esophageal squamous cell carcinoma.
Jin H; Qiao F; Chen L; Lu C; Xu L; Gao X
J Proteome Res; 2014 Sep; 13(9):4091-103. PubMed ID: 25162382
[TBL] [Abstract][Full Text] [Related]
14. Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAseq datasets.
Sharma P; Saraya A; Sharma R
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e289-e301. PubMed ID: 29380534
[TBL] [Abstract][Full Text] [Related]
15. Study on plasmatic metabolomics of Uygur patients with essential hypertension based on nuclear magnetic resonance technique.
Zhong L; Zhang JP; Nuermaimaiti AG; Yunusi KX
Eur Rev Med Pharmacol Sci; 2014; 18(23):3673-80. PubMed ID: 25535139
[TBL] [Abstract][Full Text] [Related]
16. Metabolic fingerprinting in breast cancer stages through
Suman S; Sharma RK; Kumar V; Sinha N; Shukla Y
J Pharm Biomed Anal; 2018 Oct; 160():38-45. PubMed ID: 30059813
[TBL] [Abstract][Full Text] [Related]
17.
Rawat A; Misra G; Saxena M; Tripathi S; Dubey D; Saxena S; Aggarwal A; Gupta V; Khan MY; Prakash A
Diabetes Metab Syndr; 2019; 13(1):290-298. PubMed ID: 30641714
[TBL] [Abstract][Full Text] [Related]
18. NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer.
Lin Y; Ma C; Liu C; Wang Z; Yang J; Liu X; Shen Z; Wu R
Oncotarget; 2016 May; 7(20):29454-64. PubMed ID: 27107423
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive diagnosis of papillary thyroid microcarcinoma: a NMR-based metabolomics approach.
Lu J; Hu S; Miccoli P; Zeng Q; Liu S; Ran L; Hu C
Oncotarget; 2016 Dec; 7(49):81768-81777. PubMed ID: 27835583
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
